De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Axsome Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Axsome Therapeutics' is Herriot Tabuteau, benoemd in Jan2012, heeft een ambtstermijn van 12.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.90M, bestaande uit 7.6% salaris en 92.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.015% van de aandelen van het bedrijf, ter waarde $ 649.66K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 9.8 jaar.
Belangrijke informatie
Herriot Tabuteau
Algemeen directeur
US$9.9m
Totale compensatie
Percentage CEO-salaris | 7.6% |
Dienstverband CEO | 12.8yrs |
Eigendom CEO | 0.02% |
Management gemiddelde ambtstermijn | 6.4yrs |
Gemiddelde ambtstermijn bestuur | 9.8yrs |
Recente managementupdates
Recent updates
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$309m |
Mar 31 2024 | n/a | n/a | -US$296m |
Dec 31 2023 | US$10m | US$750k | -US$239m |
Sep 30 2023 | n/a | n/a | -US$202m |
Jun 30 2023 | n/a | n/a | -US$184m |
Mar 31 2023 | n/a | n/a | -US$159m |
Dec 31 2022 | US$8m | US$685k | -US$187m |
Sep 30 2022 | n/a | n/a | -US$160m |
Jun 30 2022 | n/a | n/a | -US$150m |
Mar 31 2022 | n/a | n/a | -US$141m |
Dec 31 2021 | US$8m | US$685k | -US$130m |
Sep 30 2021 | n/a | n/a | -US$126m |
Jun 30 2021 | n/a | n/a | -US$114m |
Mar 31 2021 | n/a | n/a | -US$100m |
Dec 31 2020 | US$7m | US$575k | -US$103m |
Sep 30 2020 | n/a | n/a | -US$99m |
Jun 30 2020 | n/a | n/a | -US$95m |
Mar 31 2020 | n/a | n/a | -US$90m |
Dec 31 2019 | US$5m | US$435k | -US$68m |
Sep 30 2019 | n/a | n/a | -US$53m |
Jun 30 2019 | n/a | n/a | -US$42m |
Mar 31 2019 | n/a | n/a | -US$37m |
Dec 31 2018 | US$1m | US$435k | -US$31m |
Sep 30 2018 | n/a | n/a | -US$29m |
Jun 30 2018 | n/a | n/a | -US$27m |
Mar 31 2018 | n/a | n/a | -US$26m |
Dec 31 2017 | US$1m | US$435k | -US$29m |
Compensatie versus markt: De totale vergoeding ($USD 9.90M ) Herriot } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.75M ).
Compensatie versus inkomsten: De vergoeding van Herriot is gestegen terwijl het bedrijf verliesgevend is.
CEO
Herriot Tabuteau (56 yo)
12.8yrs
Tenure
US$9,896,629
Compensatie
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Founder | 12.8yrs | US$9.90m | 0.015% $ 659.1k | |
Chief Financial Officer | 6.4yrs | US$3.57m | 0.088% $ 3.9m | |
Chief Operating Officer | 9yrs | US$4.04m | 0.012% $ 527.4k | |
General Counsel & Secretary | 2.8yrs | US$3.06m | 0% $ 0 | |
Executive VP & Head of Commercial | less than a year | geen gegevens | geen gegevens |
6.4yrs
Gemiddelde duur
46.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AXSM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Founder | 12.8yrs | US$9.90m | 0.015% $ 659.1k | |
Independent Lead Director | 9.8yrs | US$400.34k | 0.35% $ 15.3m | |
Independent Director | 9.8yrs | US$405.34k | 0.021% $ 939.2k | |
Independent Director | less than a year | US$417.48k | 0% $ 0 | |
Independent Director | 9.8yrs | US$427.84k | 0.030% $ 1.3m |
9.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AXSM wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.8 jaar).